Acadia Pharma (ACAD) Misses Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $25.77 --0%
Revenue Growth %: +11.8%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: +11.8%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.61), $0.05 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $2.9 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Deutsche Bank Starts Porvair PLC (PRV:LN) at Buy
- Morgan Stanley Downgrades Kongsberg Gruppen ASA (KOG:NO) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
